Evolving Management Strategies for Moderate-To-Severe Atopic DermatitisLooking Beyond Barriers to Optimize Therapy
Atopic Dermatitis Overview and Pathogenesis
Barbarot S, et al. Allergy. 2018;73(6):1284-1293.
Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults.
Narla S, Silverberg JI. Ann Allergy Asthma Immunol. 2018;120(1):66-72.
Silverberg JI, Greenland P. J Allergy Clin Immunol. 2015;135(3):721-728.
Staphylococcus aureus density on lesional and nonlesional skin is strongly associated with disease severity in atopic dermatitis.
Tauber M, et al. J Allergy Clin Immunol. 2016;137(4):1272-1274.
Moving toward endotypes in atopic dermatitis: identification of patient clusters based on serum biomarker analysis.
Thijs JL, et al. J Allergy Clin Immunol. 2017;140(3):730-737.
Patient Burden and Comorbidities
The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries.
Brenaut E et al. J Eur Acad Dermatol Venereol. 2018 Jun 19. doi: 10.1111/jdv.15145. [Epub ahead of print].
Patient burden is associated with alterations in quality of life in adult patients with atopic dermatitis: results from the ECLA study.
Misery L, et al. Acta Derm Venereol. 2018;98:713-714.
Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis.
Simpson EL, et al. JAMA Dermatol. 2018;154(8):903-912.
Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab—clinical characteristics and treatment.
Wollenberg A, et al. J Allergy Clin Immunol Pract. 2018 Feb 9. doi: 10.1016/j.jaip.2018.01.034. [Epub ahead of print].
Management of Atopic Dermatitis
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, et al. Lancet. 2017;389(10086):2287-2303.
Dupilumab with concomitant topical corticosteroids in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A, or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ).
de Bruin-Weller M, et al. Br J Dermatol. 2018;178(5):1083-1101.
Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement.
Drucker AM, et al. Br J Dermatol. 2018;178(3):768-775.
Eichenfield LF, et al. Pediatrics. 2015;136(3):554-565.
Ruzicka T, et al. N Engl J Med. 2017;376(9):826-835.
Simpson EL, et al. N Engl J Med. 2016;375(24):2335-2348.
Clinical Insights Into Atopic Dermatitis Pathogenesis
Narrated by Jeffrey M.Weinberg, MD
Discussions and Debates About Managing Moderate-to-Severe Disease
Debates and Discussions About Managing Moderate-to-Severe Disease
Improved Diagnostic and Management Strategies
Long-Term Management Strategies to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Evolving Strategies for Diagnosis and Long-Term Management
Treating to Target, IL-6-Directed Therapies, and Evolving Management Algorithms
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Pathophysiology to the Management of Moderate-to-Severe Disease
New Strategies to Target Remission and Individualize Comprehensive Care
Targeting Immune Dysregulation and Delivering Comprehensive Care
Translating Comprehensive Patient Evaluations Into Personalized Therapy
New Perspectives on Targeting Remission and Individualizing Therapy
Using Imaging to Improve Patient Outcomes
Discussions and Debates on the Evolving Roles of Targeted Synthetic DMARDs
Translating Pathophysiology into Targeted Treatments